Patents by Inventor Weiqiang XING

Weiqiang XING has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETEROCYCLIC GLP-1 AGONISTS
    Publication number: 20250145596
    Abstract: Provided are GLP-1 agonists and pharmaceutical compositions comprising the same, as well as methods for treating a GLP-1 associated disease, disorder, or condition.
    Type: Application
    Filed: February 8, 2023
    Publication date: May 8, 2025
    Inventors: Qinghua MENG, Weiqiang XING
  • HETEROCYCLIC GLP-1 AGONISTS
    Publication number: 20250115606
    Abstract: This disclosure relates to GLP-1 agonists of Formula (I), including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
    Type: Application
    Filed: December 17, 2024
    Publication date: April 10, 2025
    Inventors: Qinghua MENG, Weiqiang XING, Haizhen ZHANG, Xichen LIN, Hui LEI, Andrew JENNINGS
  • HETEROCYCLIC GLP-1 AGONISTS
    Publication number: 20250109148
    Abstract: It relates generally to GLP-1 agonists and pharmaceutical compositions comprising the same, as well as methods for treating a GLP-1 associated disease, disorder, or condition.
    Type: Application
    Filed: January 20, 2023
    Publication date: April 3, 2025
    Inventors: Wei HUANG, Hui LEI, Qinghua MENG, Fan WU, Weiqiang XING, Haizhen ZHANG
  • Phthalazinone compound, and preparation method therefor and medical use thereof
    Patent number: 12234223
    Abstract: Disclosed are a phthalazinone compound, and a preparation method therefor and the medical use thereof. In particular, disclosed are a compound as represented by formula (I), and a pharmacodynamically acceptable salt, and the use of the compound as an androgen receptor (AR) for degradation.
    Type: Grant
    Filed: August 14, 2024
    Date of Patent: February 25, 2025
    Assignees: SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD., JIANGXI JEMINCARE GROUP CO., LTD
    Inventors: Hongfu Lu, Weiqiang Xing, Yongcong Lv, Baojian Qi, Jianbiao Peng, Haibing Guo
  • Heterocyclic GLP-1 agonists
    Patent number: 12221442
    Abstract: This disclosure relates to GLP-1 agonists of Formula (I), including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
    Type: Grant
    Filed: January 26, 2024
    Date of Patent: February 11, 2025
    Assignee: Gasherbrum Bio, Inc.
    Inventors: Qinghua Meng, Weiqiang Xing, Haizhen Zhang, Xichen Lin, Hui Lei, Andrew Jennings
  • Aromatic ring derivative as immunoregulation and preparation method and application of aromatic ring derivative
    Patent number: 12195457
    Abstract: Relating to a compound represented by formula (I) and a pharmaceutically acceptable salt of the compound, and an application of the compound as an S1P1 agonist.
    Type: Grant
    Filed: December 6, 2019
    Date of Patent: January 14, 2025
    Assignees: SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD;, JIANGXI JEMINCARE GROUP CO., LTD
    Inventors: Hongfu Lu, Jianbiao Peng, Weiqiang Xing, Haibing Guo
  • PHTHALAZINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF
    Publication number: 20240400540
    Abstract: Disclosed are a phthalazinone compound, and a preparation method therefor and the medical use thereof. In particular, disclosed are a compound as represented by formula (I), and a pharmacodynamically acceptable salt, and the use of the compound as an androgen receptor (AR) for degradation.
    Type: Application
    Filed: August 14, 2024
    Publication date: December 5, 2024
    Inventors: Hongfu Lu, Weiqiang Xing, Yongcong Lv, Baojian Qi, Jianbiao Peng, Haibing Guo
  • HETEROCYCLIC GLP-1 AGONISTS
    Publication number: 20240366639
    Abstract: GLP-1 agonists of Formula (I): including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
    Type: Application
    Filed: August 12, 2022
    Publication date: November 7, 2024
    Inventors: Qinghua MENG, Xichen LIN, Haizhen ZHANG, Weiqiang XING, Hui LEI, Andrew JENNINGS
  • HETEROCYCLIC GLP-1 AGONISTS
    Publication number: 20240246962
    Abstract: This disclosure relates to GLP-1 agonists of Formula (I), including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
    Type: Application
    Filed: January 26, 2024
    Publication date: July 25, 2024
    Inventors: Qinghua MENG, Weiqiang XING, Haizhen ZHANG, Xichen LIN, Hui LEI, Andrew JENNINGS
  • HETEROCYCLIC GLP-1 AGONISTS
    Publication number: 20240083886
    Abstract: Relates to GLP-1 agonists of Formula (I): including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
    Type: Application
    Filed: October 13, 2021
    Publication date: March 14, 2024
    Inventors: Qinghua MENG, Weiqiang XING, Xichen LIN, Andrew JENNINGS
  • Heterocyclic GLP-1 agonists
    Patent number: 11926626
    Abstract: This disclosure relates to GLP-1 agonists of Formula (I), including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
    Type: Grant
    Filed: September 21, 2022
    Date of Patent: March 12, 2024
    Assignee: Gasherbrum Bio, Inc.
    Inventors: Qinghua Meng, Weiqiang Xing, Haizhen Zhang, Xichen Lin, Hui Lei, Andrew Jennings
  • Heterocyclic GLP-1 agonists
    Patent number: 11926643
    Abstract: This disclosure relates to GLP-1 agonists of Formula (I): including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
    Type: Grant
    Filed: June 29, 2022
    Date of Patent: March 12, 2024
    Assignee: Gasherbrum Bio, Inc.
    Inventors: Qinghua Meng, Xichen Lin, Haizhen Zhang, Weiqiang Xing, Hui Lei, Andrew Jennings
  • HETEROCYCLIC GLP-1 AGONISTS
    Publication number: 20230391760
    Abstract: This disclosure relates to GLP-1 agonists of Formula (I): including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
    Type: Application
    Filed: October 13, 2021
    Publication date: December 7, 2023
    Inventors: Qinghua MENG, Weiqiang XING, Xichen LIN, Andrew JENNINGS
  • HETEROCYCLIC GLP-1 AGONISTS
    Publication number: 20230331732
    Abstract: This disclosure relates to GLP-1 agonists of Formula (I), including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
    Type: Application
    Filed: September 8, 2021
    Publication date: October 19, 2023
    Inventors: Qinghua MENG, Weiqiang XING, Haizhen ZHANG, Xichen LIN, Hui LEI, Andrew JENNINGS
  • HETEROCYCLIC GLP-1 AGONISTS
    Publication number: 20230322771
    Abstract: This disclosure relates to GLP-1 agonists of Formula (I), including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
    Type: Application
    Filed: September 6, 2021
    Publication date: October 12, 2023
    Inventors: Qinghua MENG, Weiqiang XING, Haizhen ZHANG, Xichen LIN, Hui LEI, Andrew JENNINGS
  • Phthalazinone compound, and preparation method therefor and medical use thereof
    Patent number: 11767312
    Abstract: Disclosed are a phthalazinone compound, and a preparation method therefor and the medical use thereof. In particular, disclosed are a compound as represented by formula (I), and a pharmacodynamically acceptable salt, and the use of the compound as an androgen receptor (AR) for degradation.
    Type: Grant
    Filed: April 5, 2023
    Date of Patent: September 26, 2023
    Assignee: GENENTECH, INC.
    Inventors: Hongfu Lu, Weiqiang Xing, Yongcong Lv, Baojian Qi, Jianbiao Peng, Haibing Guo
  • PHTHALAZINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF
    Publication number: 20230242510
    Abstract: Disclosed are a phthalazinone compound, and a preparation method therefor and the medical use thereof. In particular, disclosed are a compound as represented by formula (I), and a pharmacodynamically acceptable salt, and the use of the compound as an androgen receptor (AR) for degradation.
    Type: Application
    Filed: April 5, 2023
    Publication date: August 3, 2023
    Inventors: Hongfu Lu, Weiqiang Xing, Yongcong Lv, Baojian Qi, Jianbiao Peng, Haibing Guo
  • HETEROCYCLIC GLP-1 AGONISTS
    Publication number: 20230174565
    Abstract: This disclosure relates to GLP-1 agonists of Formula (I): including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
    Type: Application
    Filed: June 29, 2022
    Publication date: June 8, 2023
    Inventors: Qinghua MENG, Xichen LIN, Haizhen ZHANG, Weiqiang XING, Hui LEI, Andrew JENNINGS
  • PHTHALAZINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF
    Publication number: 20230131252
    Abstract: Disclosed are a phthalazinone compound, and a preparation method therefor and the medical use thereof. In particular, disclosed are a compound as represented by formula (I), and a pharmacodynamically acceptable salt, and the use of the compound as an androgen receptor (AR) for degradation.
    Type: Application
    Filed: December 12, 2022
    Publication date: April 27, 2023
    Inventors: Hongfu Lu, Weiqiang Xing, Yongcong Lv, Baojian Qi, Jianbiao Peng, Haibing Guo
  • PROTEIN DEGRADATION AGENT COMPOUND PREPARATION METHOD AND APPLICATION
    Publication number: 20230111119
    Abstract: Provided are a protein degradation agent compound preparation method and application; specifically, provided are the compound represented by formula (I) and a pharmacologically acceptable salt thereof, and an application of said compound in the degradation of androgen receptor (AR).
    Type: Application
    Filed: December 23, 2020
    Publication date: April 13, 2023
    Inventors: Hongfu LU, Weiqiang XING, Baojian QI, Jianbiao PENG, Haibing GUO